Ascendis TransCon PTH Shows Sustained 5-Year Kidney Function Gains in Hypoparathyroidism
ASND sits 30% above its 52-week low of $188.071.
Summary
Ascendis presented pooled 5-year data showing TransCon PTH durably improved kidney function and freed nearly all hypoparathyroidism patients from conventional vitamin D and calcium therapy, with no new safety signals.
Key Events · Product Development and Regulatory · ASND
-
Sustained eGFR Gains Through 5 Years
Mean eGFR rose 7.2 mL/min/1.73 m2 at Week 26 and 9.6 mL/min/1.73 m2 at Week 52 (p<0.0001), then held a slope of 0.28 mL/min/1.73 m2/year from Week 52 to Week 266.
-
Most Patients Off Conventional Therapy
At final visit, 98% achieved independence from active vitamin D and 95% from therapeutic calcium; 88% had normal albumin-adjusted serum calcium.
-
Urine Calcium Normalized
24-hour urine calcium fell from 396 mg/day at baseline to 206 mg/day at Week 26 and 170 mg/day at Week 52, sustained through trial end.
-
Safety Profile Unchanged
No new safety signals across 141 adults in the two trials; most adverse events were Grade 1 or 2.
Analysis · ASND · Life Sciences
Pooled PaTH Forward and PaTHway data show TransCon PTH improved eGFR by 9.6 mL/min/1.73 m2 at Week 52 and held a near-flat slope of 0.28 mL/min/1.73 m2/year out to Week 266 — the opposite of the age-related kidney decline expected in these adults. Nearly all patients (98%) came off active vitamin D and 95% off therapeutic calcium, which matters commercially because it reframes the drug from symptom control to organ-level benefit. That is the kind of label-expanding evidence that supports payer and physician adoption, though this is post-hoc pooled analysis rather than a new controlled trial.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASND was trading at $245.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.3B. The 52-week trading range was $188.07 to $282.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.